

**Rinvoq (upadacitinib)
Effective 01/01/21**

Plan	<input type="checkbox"/> MassHealth <input checked="" type="checkbox"/> MassHealth (PUF) <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input checked="" type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions	N/A		

Overview

Rinvoq is a Janus kinase (JAK) inhibitor FDA indicated for moderately to severely active rheumatoid arthritis. Janus kinase (JAK) enzymes, are intracellular enzymes involved in stimulating hematopoiesis and immune cell function through a signaling pathway. JAKs activate signal transducers and activators of transcription (STATs) which regulate gene expression and intracellular activity. The inhibition of JAKs prevents the activation of STATs.

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members new to AllWays Health Partners who are currently receiving treatment with Rinvoq excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR

Authorization may be granted for members when ALL the following criteria are met, and documentation is provided:

Moderate to Severe Rheumatoid Arthritis (RA)

Prescriber provides documentation of ALL the following:

1. Appropriate diagnosis
2. Paid claims or physician documented inadequate response or adverse reaction to ONE traditional DMARD or contraindication to traditional DMARDs
3. ONE of the following:
 - a. Paid claims or physician documented inadequate response or adverse reaction to ONE biologic DMARD that is FDA-approved for RA
 - b. Contraindication to ALL biologic DMARDs FDA-approved for RA



4. Paid claims or physician documented inadequate response, adverse reaction or contraindication to Xeljanz® (tofacitinib) or Xeljanz XR® (tofacitinib extended-release)
5. Quantity requested is ≤ 1 tablet/day

Continuation of Therapy

Reauthorization requires physician documentation of continuation of therapy, positive response to therapy, FDA approved indication and appropriate dosing.

Limitations

1. Initial authorizations will be approved for 6 months
2. Reauthorizations will be approved for 12 months
3. The following quantity limits apply:

Rinvoq 15mg	30 tablets per 30day
-------------	----------------------

References

1. Rinvoq (upadacitinib) [prescribing information]. North Chicago, IL: AbbVie Inc; August 2019
2. O'Dell JR, Curtis JR, Mikuls TR, et al. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial. *Arthritis Rheum* 2013; 65:1985
3. Food and Drug Administration Center for Drug Evaluation and Research. Summary Minutes of the Arthritis Advisory Committee Meeting. August 2, 2017
<https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM575678.pdf> (Accessed on October 02, 2018)
4. Bonilla-Hernán MG, Miranda-Carús ME, Martin-Mola E. New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors. *Rheumatology (Oxford)* 2011; 50:1542

Review History

11/20/2019 – Reviewed at P&T

03/18/2020 – Reviewed and Updated Mtg; added MH LOB; checked off QL (effective 6/1/20)

10/21/2020 – Reviewed and Updated; separated out Comm/Exch vs. MassHealth. Matched MassHealth Preferred Unified Formulary for implementation 1/1/2021

Disclaimer

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.